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Abstract: Colchicinoids are very potent tubulin-binding compounds, which interfere with 
microtubule formation, giving them strong cytotoxic properties, such as cell mitosis   inhibition 
and induction of microcytoskeleton depolymerization. While this makes them promising   vascular 
disrupting agents (VDAs) in cancer therapy, their dose-limiting toxicity has prevented any   clinical 
application for this purpose. Therefore, colchicinoids are considered attractive lead molecules 
for the development of novel vascular disrupting nanomedicine. In a previous study, a polymeric 
colchicinoid prodrug that showed favorable hydrolysis characteristics at   physiological condi-
tions was developed. In the current study, this polymeric colchicinoid prodrug was evaluated 
in vitro and in vivo for its toxicity and vascular disrupting potential. Cell viability studies with 
human umbilical vein endothelial cells, as an in vitro measure for colchicine activity, reflected 
the degradation kinetics of the prodrug accordingly. Upon intravenous treatment, in vivo, of 
B16F10 melanoma-bearing mice with colchicine or with the polymeric colchicinoid prodrug, 
apparent vascular disruption and consequent tumor necrosis was observed for the prodrug but 
not for free colchicine at an equivalent dose. Moreover, a five-times-higher dose of the prodrug 
was well tolerated, indicating reduced toxicity. These findings demonstrate that the polymeric 
colchicinoid prodrug has a substantially improved efficacy/toxicity ratio compared with that of 
colchicine, making it a promising VDA for cancer therapy.
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Introduction
The extract of Colchicum autumnale, which is more commonly known as autumn 
crocus, wild saffron, naked lady, or any of several other names, has been used in the 
therapy of gout for more than 15 centuries.1 At present, it is still in clinical use for the 
treatment of gout, as well as several other inflammatory diseases including familial 
Mediterranean fever and Behçet’s disease.2,3 Colchicine and its colchicinoid deriva-
tives possess the ability to bind irreversibly to tubulin, forming tubulin-colchicine 
complexes, which hinder microtubule formation and inhibit cell mitosis.2–4 It has been 
described that colchicine possesses anti-inflammatory properties, mainly mediated by 
inhibition of leukocyte adhesion and activity.2,5 At higher doses, tubulin-colchicine 
complexes induce depolymerization of microtubules, resulting in destabilization 
of the tubulin cytoskeleton.4,6,7 Whereas most cells rely on actin for their cell mor-
phology, endothelial cells of angiogenic tumor vasculature are more dependent on 
tubulin to maintain their typically enlongated shape.6,8 Therefore, upon colchicinoid-
induced microtubule depolymerization, the tumor endothelial cells lose their shape, 
thereby exposing the vascular basement membrane, which subsequently leads to 
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coagulation, decreased perfusion, and hemostasis.9,10 This 
process, known as vascular disruption, deprives the sur-
rounding (tumor) cells of oxygen and nutrients, leading 
to massive tissue necrosis. Currently, however, there is no 
use for colchicine and colchicinoids in cancer therapy due 
to their high systemic toxicity.11 Although in preclinical 
cancer models doses of colchicine higher than 5 mg/kg 
induce a significant reduction in the perfusion of tumors, the 
maximum tolerated dose (MTD) of colchicine is limited to 
around 1 mg/kg.12,13 Even doses below 0.5 mg/kg, as used 
in the clinical management of gout and familial Mediter-
ranean fever, are frequently accompanied by gastrointestinal 
comorbidity (eg, nausea, vomiting, and diarrhea) and hema-
tologic disorders, such as   thrombocytopenia.14 Colchicine 
doses higher than 0.5 mg/kg are generally considered 
toxic, although lower doses may still cause significant side 
effects, illustrating its narrow therapeutic index.   Overdosing 
of colchicine may eventually lead to multiple organ   failure, 
including bone marrow suppression, hemolysis, liver fail-
ure, renal failure, convulsions, and cardiac arrest, and is 
often lethal.14,15
One strategy to limit the side effects caused by colchi-
cinoid therapy is to design colchicinoid prodrugs, which 
possess pharmacological activity only upon conversion.16 
Colchicinoids have a partition coefficient (log P) of around 1 
and a relatively high volume of distribution (±2 L/kg), which 
implies that upon intravenous injection they immediately 
redistribute into the tissues, explaining the high risk for side 
effects.17–19 Therefore, by creating a colchicinoid prodrug 
with improved aqueous solubility, its volume of distribu-
tion is expected to be reduced, confining its distribution to 
the circulation and extracellular compartment and lower-
ing its off-target toxicity. Additionally, to keep the prodrug 
in the proximity of its target cells, that is, the angiogenic 
endothelial cells, the tissue penetration of the prodrug may 
be reduced by increasing its molecular weight. Previously, 
colchicinoid prodrugs based on glycopeptide dendrimers and 
cobalamin (vitamin B12) have been synthesized and char-
acterized in vitro.20,21 However, to be converted to the active 
colchicinoid, both conjugates required cellular uptake in the 
tumor tissue. For exploiting the direct cytotoxic activity of 
colchicinoids – the inhibition of tumor cell mitosis – this 
is a rational approach. For colchicinoid-induced vascular 
disruption, however, a colchicinoid prodrug that is converted 
extracellularly, preferably in the proximity of the tumor 
vascular endothelium, is needed. This may be achieved by 
utilizing polymer-based colchicinoid prodrugs that are more 
readily transformed into the active colchicinoid, such as 
by hydrolysis of an ester bond which allows conversion in 
aqueous conditions. Previous work reported the synthesis 
of a hydrophilic colchicinoid prodrug, where colchicine 
was derivatized and conjugated to poly(ethylene glycol) 
(PEG) using a linker liable to hydrolysis.22 The synthesis of 
nanomedicines by conjugating PEG-chains (PEGylation) 
to low-molecular-weight drugs increases the hydrophilicity 
and size of the construct, and shields them from interactions 
with plasma proteins.23–25 Upon intravenous injection, instan-
taneous and random diffusion of the colchicinoid prodrug 
into cells is impeded by the relatively large PEG moiety, 
thereby preventing the binding to tubulin and limiting its 
toxicity. However, due to the enhanced permeability of the 
imperfect angiogenic vasculature, the nanosized colchici-
noid prodrug may be passively targeted to the tumor tissue, 
where, promoted by the reductive microenvironment in the 
tumor tissue, it hydrolyzes to the active colchicinoid.26 In the 
present study, a polymeric colchicinoid prodrug containing 
a hydrolysable linker was studied in vitro and in vivo for 
its therapeutic potential and toxicity as vascular disrupting 
agent.
Materials and methods
Synthesis of polymeric colchicinoid 
prodrug
Colchicine was derived and conjugated to PEG5000 using 
methodology reported elsewhere (Figure 1).22 In brief, colchi-
cine was hydroxyl-functionalized by substituting the N-acetyl 
moiety with an N-2-hydroxyacetyl moiety. Subsequently, the 
hydroxyl group was reacted with methoxy PEG-acetic acid 
to obtain the hydrolysable polymeric colchicinoid prodrug. 
The amount of colchicine derivative per milligram of   material 
(ie, colchicine equivalents) was determined by means of 
ultra performance liquid chromatography (UPLC) using an 
Acquity UPLC® BEH C18 1.7 µm column (Waters, Milford, 
MA) and ultraviolet detection at 350 nm (Acquity UPLC® 
PDA; Waters). The mobile phase consisted of a gradient 
from 5%–95% methanol in water (v/v) and trifluoroacetic 
acid as modifier.
In vitro hydrolysis study
The hydrolysis kinetics of the colchicinoid prodrug were 
determined at 4°C and 37°C in phosphate buffer (20 mM, 
pH 7.4). During 72 hours, samples were taken at regular 
time intervals, and stored at −20°C before analysis. For each 
time point, the concentration of colchicinoid prodrug and 
hydrolyzed prodrug were determined by UPLC, using the 
methodology described in the previous section.
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In vitro cytotoxicity
Human umbilical vein endothelial cells (HUVECs) were 
grown at 37°C and 5% carbon dioxide in angiogenic growth 
factor rich EGM®-2 medium (Lonza Ltd, Basel, Switzerland). 
Cells were seeded in 96-well plates (1 × 104 cells/well) for 
24 hours before further treatment. Subsequently, the cells 
were incubated with colchicine and colchicinoid prodrug 
at concentrations ranging from 0.025–2.5 µM colchicine 
  equivalents. The cytotoxicity of each drug after 6 hours, 
24 hours, and 48 hours incubation was determined by colo-
rimetric XTT (2,3-bis-(2-methoxy-4-nitro-5-sulfophenyl)-
  2H-tetrazolium-5-carboxanilide) cell viability assay.27
In vivo vascular disrupting efficacy  
of colchicinoid prodrug
All animal experiments were conducted in agreement with the 
local applicable Dutch law, “Wet op de dierproeven” (1977),28 
and the European Convention for the   Protection of Vertebrate 
Animals used for Experimental and Other Scientific Purposes 
(1986).29 The mice were housed in steel cages, and water 
and food were provided ad libitum. Female pathogen-free 
C57BL/6 inbred mice of 21–24 g (Charles River   Laboratories 
International, Inc,   Wilmington, MA) were subcutaneously 
inoculated with 1 × 106 B16F10 cells. Ten days after tumor 
cell inoculation, when tumor size reached .100 mm3, phos-
phate buffered saline, colchicine (1 mg/kg), and the colchici-
noid prodrug (1 mg/kg and 5 mg/kg, colchicine equivalents) 
were administered intravenously in the tail vein. The mice were 
sacrificed at 4 and 24 hours after injection. The tumors were 
excised, snap frozen in liquid nitrogen, and stored at −80°C 
upon sectioning.
Histological evaluation
Frozen tumor samples (n = 3 per group) were sectioned 
(5 µm), acetone fixed, and hematoxylin and eosin stained. 
Images were taken with an inverted microscope (Nikon 
Eclipse TE2000U; Nikon Corporation, Tokyo, Japan) using 
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Figure 1 Synthesis and hydrolysis kinetics of colchicinoid prodrug. The synthesis of the colchicinoid prodrug is performed in three steps: (1) colchicine is deacetylated to 
obtain N-deacetylcolchicine; (2) N-deacetylcolchicine is acylated with glycolic acid resulting in a hydroxyl functionalized colchicinoid also known as colchifoline; and (3) the 
colchicinoid is coupled to methoxy PEG5000 to form the colchicinoid prodrug. By using esterification to conjugate PEG to the colchicinoid, a prodrug that is hydrolysable at 
physiological conditions is created: at 37°C, the prodrug is cleaved within a day (t1/2 5.4 hours), while at 4°C the hydrolysis rate is limited (calculated t1/2 14 days [zero-order 
kinetics]).
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NIS Elements software (Nikon Corporation). Small magnifi-
cation (10×) overlapping images were taken of the complete 
tumor area and subsequently stitched together with PhotoFit 
(v 1.4; Tekmate, Inc, Anchorage, AK) software.
Results and discussion
Although colchicine is widely recognized as a promis-
ing VDA for cancer therapy, its dose-limiting toxicity 
has prevented it from realising this potential.11 Only by 
dosing colchicine well above its MTD, could significant 
vascular disruption and subsequent necrosis of tumor 
tissue be observed.12,13 In the present study, a PEG-based 
polymeric nanomedicine of colchicine was synthesized to 
attenuate systemic toxicity and to enhance its therapeutic 
index by improving its aqueous solubility. To this end, 
colchicine was derived and conjugated to PEG5000 via a 
hydrolysable linker (Figure 1). The molecular structure of 
colchicine was modified at the acetamido moiety, which 
is not part of the pharmacophore, creating a colchicinoid 
also known as colchifoline, with similar anti-inflammatory 
and tubulin-binding activity.7,30,31 Hydrolysis studies at 
physiological conditions (37°C, pH 7.4) showed that the 
half-life of prodrug conversion was approximately 5 hours, 
whereas, this was calculated by zero-order extrapolation at 
approximately 14 days at low temperature (Figure 1). The 
conversion rate of the prodrug at physiological conditions 
correlated with its activity in endothelial cell viability 
experiments. To investigate the antimitotic tubulin-binding 
capacity as a measure of efficacy, colchicine and the 
colchicinoid prodrug were incubated at different concentra-
tions (0.025–2.5 µM, colchicine equivalent) with primary 
HUVECs (Figure 2). After 6 hours of incubation, few or 
no apparent effects on cell viability were measured for 
each treatment (two-way analysis of variance, P . 0.05), 
indicating that several hours of incubation are needed 
to allow colchicine to interfere with tubulin dynamics. 
  However, after 24 hours and 48 hours of incubation, 
HUVEC viability was markedly decreased for both colchi-
cine (dose $ 0.025 µM, P , 0.001) and the polymeric 
colchicinoid prodrug (dose $ 0.125 µM, P , 0.001). The 
prodrug, of which .95% is converted after 24 hours at 
37°C, showed at the highest doses a similar cytotoxicity 
in comparison with colchicine. However, at lower con-
centrations the prodrug was less potent than colchicine 
after 24 hours and 48 hours incubation (P , 0.05, 0.125– 
0.25 µM at 24 hours; 0.025–0.25 µM at 48 hours), despite 
the fact that practically all prodrug has been converted at 
these time points. The lower activity of the prodrug can be 
explained by the delayed availability of the colchicinoid 
due to the time needed for conversion of the prodrug.
The in vivo efficacy and toxicity of colchicine and the 
colchicinoid prodrug as VDAs in solid tumors were assessed 
in mice bearing subcutaneous B16F10 melanoma tumors. 
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Figure 2 In vitro cytotoxicity of colchicine and colchicinoid prodrug. The endothelial 
cell  toxicity  of  colchicine  and  the  colchicinoid  prodrug  were  determined  as  a 
measure of their ability to induce damage to angiogenic vasculature. Human umbilical 
vein  endothelial  cells  were  incubated  with  colchicine  and  colchicinoid  prodrug 
at  different  equivalent  concentrations  during  6  hours,  24  hours,  and  48  hours. 
Subsequently, the cell viability in respect to the untreated cells was determined by 
XTT assay. Whereas there was only low reduction in cell viability and no difference 
between the treatments after 6 hours of incubation, the colchicinoid prodrug was 
less cytotoxic than colchicine at 24 hours (0.125 µM and 0.25 µM, P , 0.05, two-
way analysis of variance) and 48 hours (0.025–0.25 µM, P , 0.05).
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To study the systemic toxicity, the weight of the mice was 
determined before and 24 hours after intravenous treatment 
with either colchicine or the prodrug. Approximately 8% 
of total body weight was lost 24 hours after administration 
of 1 mg/kg colchicine (P , 0.05 one-tailed paired t-test) 
(Figure 3). The high loss of body weight at 24 hours after 
treatment with 1 mg/kg colchicine illustrates the high toxic-
ity of colchicine, which limits the maximum dose to a level 
considered insufficient to result in VDA activity.13 However, 
at 1 mg/kg colchicine equivalent dose, the polymeric prod-
rug did not induce significant weight loss, and only upon 
administration of a 5× higher dose (5 mg/kg), did it cause 
a drop in average body weight similar to that of colchicine 
at its MTD (12%, P , 0.05). This much higher tolerability 
of the prodrug compared with free colchicine may therefore 
allow for colchicinoid doses more likely to result in vascular 
disrupting activity.
The mice were sacrificed at 4 and 24 hours after treat-
ment and the tumors were excised, sectioned, and stained 
to examine vascular disruption-induced tissue necrosis. No 
tumor necrosis was observed at 4 hours (Figure 4A and B) 
or 24 hours (data not shown) after intravenous injection of 
phosphate buffered saline or colchicine dosed at its MTD 
(1 mg/kg). The polymeric colchicinoid prodrug, however, 
induced tissue necrosis in multiple areas in the tumors 
4 hours after administration at colchicine equivalent doses 
of 1 mg/kg and 5 mg/kg (Figure 4C and D, respectively). 
A similar extent of necrosis (approximately 50% of total 
tumor mass) was seen after 24 hours in the tumors of mice 
treated with colchicine equivalents of 1 mg/kg or 5 mg/kg of 
colchicinoid prodrug (Figure 4E and F). Although it has been 
shown previously for colchicine that intravenous doses of 
5 mg/kg or higher are required to induce observable vascular 
disruption and subsequent necrosis in solid tumors,12,13 the 
polymeric colchicinoid prodrug exhibited vascular disrupting 
efficacy at a much lower dose (1 mg/kg), despite its reduced 
potency in vitro.
Polymer conjugation is a successful strategy in prodrug 
development that has been employed regularly for improv-
ing the aqueous solubility of the parent compound.25 An 
improved aqueous solubility changes the tissue distribution, 
which might explain the potency of the colchicinoid prod-
rug in relation to colchicine.16 By employing a PEG-chain 
larger than 35 kDa, or by utilizing colloidal drug delivery 
systems such as liposomes, a significant decrease in plasma 
clearance of the colchicinoid prodrug may be achieved, 
potentially enhancing its in vivo efficacy even more.25,32,33 
Nevertheless, the vascular disrupting efficacy at a low, 
nontoxic dose makes the polymeric colchicinoid prodrug 
presented here a promising VDA for cancer therapy. The 
observed favorable characteristics of the prodrug in vivo, 
on one hand, may be related to enhanced accumulation of 
the prodrug in the tumor tissue mediated by its improved 
aqueous solubility, limiting its distribution into other tissues 
and allowing it to penetrate via the “leaky” immature tumor 
vasculature.34 On the other hand, the increased expression 
and activity of reductive enzymes, such as esterases and 
carboxylesterases, in tumor and endothelial cells may 
augment tumor-specific conversion of the prodrug into the 
active colchicinoid, and thus improve its efficacy at the 
target site, while the polymer conjugation, as such, limits 
its toxicity toward other healthy tissues.26,35–39
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Figure 3 Effect of in vivo toxicity of colchicine and colchicinoid prodrug on the body weight of mice. To study their in vivo toxicity, colchicine (1 mg/kg) and the colchicinoid 
prodrug (1 mg/kg and 5 mg/kg colchicine equivalents) were intravenously injected into B16F10 melanoma-bearing mice. The weight of the mice was measured upon injection 
(0 hours, white bars) and 24 hours (black bars) after injection.
Notes: Significant weight loss was observed for mice treated with 1 mg/kg colchicine (7.7%, P = 0.0371, one-tailed paired t-test) and 5 mg/kg colchicinoid prodrug (12.0%, 
P = 0.0175) (indicated by *), but not for mice treated with 1 mg/kg colchicinoid prodrug (0%, P . 0.05) (indicated by NS).
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Conclusion
The vascular disrupting efficacy and toxicity of a hydrolys-
able polymeric colchicinoid prodrug was studied in vitro 
and in vivo. The presented data convincingly demonstrate 
that the rate of hydrolysis of the prodrug at physiological 
conditions correlates with its reduced in vitro efficacy 
compared with colchicine. In vivo, the colchicinoid 
prodrug was found to be less toxic, while showing higher 
VDA efficacy than the parent compound, colchicine. 
Taken together, this study demonstrates the employment 
of a promising prodrug strategy using a polymeric nano-
medicine for improving the vascular disrupting efficacy 
of colchicinoids while reducing their systemic toxicity, 
thereby opening the door for the application of these potent 
VDAs in cancer therapy.
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